Retatrutide

An investigational triple-receptor agonist studied in metabolic-research literature.

Retatrutide is catalogued here as a reference compound for metabolic-regulation research. The entry covers its chemical identity and the public databases that describe it; it is not a usage guide.

Retatrutide appears in the metabolic-regulation literature, primarily in in-vitro and preclinical (animal) models. This page indexes 4 verified primary papers on Retatrutide (3 rodent and 1 review), each resolvable by PMID or DOI. Peptidoteca summarizes the proposed mechanism class and the primary sources rather than human outcomes; for the wider library, see the research library.

Attributed, study-level findings from the verified literature indexed on this page — preclinical observations, not clinical outcomes:

• Briand F et al. (2026), Obesity (Silver Spring) [rodent] — In preclinical diet-induced obese MASH mouse and hamster models, the triple GIP/GLP-1/glucagon receptor agonist retatrutide was reported to reduce body weight, hepatic steatosis and liver triglycerides, and HOMA-IR insulin resistance, with changes in food intake. Findings are limited to these animal models and do not establish human efficacy.
• Perez-Tilve D et al. (2026), Molecular Metabolism [rodent] — In this rodent study, the GLP-1R:GIPR:GCGR triagonist retatrutide was reported to normalize body weight in diet-induced obese GLP-1R-knockout mice, indicating retatrutide-driven weight reduction can occur without functional GLP-1 receptor signaling; a GIPR:GCGR co-agonist lacking GLP-1 activity lowered excess body weight comparably.
• Li Q et al. (2026), Diabetology & Metabolic Syndrome [rodent] — In a high-fat-diet mouse model, multi-omic profiling reported that the GIP/GLP-1/glucagon triple agonist retatrutide was associated with reduced adipose-tissue fibrosis — downregulated inflammatory/fibrotic pathways and upregulated reparative signaling — alongside metabolic reprogramming toward fatty-acid oxidation and improved mitochondrial function.
• Ganamurali N et al. (2026), Clinical Pharmacology in Drug Development [review] — This review characterizes retatrutide (LY3437943) in the literature as a single-molecule triple receptor agonist acting on the GLP-1, GIP, and glucagon receptors, situating it within the broader development of multi-hormonal peptide pharmacology described for obesity and cardiometabolic comorbidities.

No. Retatrutide is supplied for laboratory (in-vitro) research use only. It is not approved by the FDA or any comparable regulator for human or veterinary use, and nothing on this page constitutes medical advice, dosing guidance or a treatment recommendation.

Most available evidence for Retatrutide is preclinical — in-vitro and animal models — and findings in those models do not establish efficacy or safety in humans. Human clinical data is limited or absent, and Retatrutide is not an approved drug. Treat the literature as mechanistic research, not clinical guidance.